Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Inflammatory Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-12RB1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-12RB1 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View IL-12RB1 Products |
| Gene Delivery | IL-12RB1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for preserving native conformation in flow cytometry. |
View IL-12RB1 Products |
| Benchmark Ab | Anti-IL-12RB1 Recombinant Antibody Sequence-derived positive control for binding and blocking assays. |
View IL-12RB1 Products |
| Validator | IL-12RB1 siRNA Set Target-specific knockdown verification in primary cells or cell lines. |
View IL-12RB1 Products |
| Related Target A | IL-12RB2 Co-receptor subunit that heterodimerizes with IL-12RB1 to form the functional IL-12 receptor complex. |
View IL-12RB2 Products |
| Related Target B | IL-23R Co-receptor subunit that heterodimerizes with IL-12RB1 to form the functional IL-23 receptor complex. |
View IL-23R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Differentiating IL-12 vs. IL-23 pathway blockade | High-purity IL-12RB1, IL-12RB2, and IL-23R monomeric/chimeric proteins available for comparative SPR/BLI binding kinetics. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Validated siRNA included for specificity and functional knockdown checks in cell-based assays. |
Live IL-12RB1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-12RB1 therapeutics is intensifying, with major players shifting focus from traditional systemic cytokine-blocking mAbs (such as anti-p40) to receptor-specific modulation. As first-generation therapies reach the clinic, the next wave of R&D is targeting selective receptor subunit blockade to spare homeostatic pathways while shutting down pathogenic Th1/Th17 signaling. IL-12RB1 serves as the common subunit for both IL-12 and IL-23 receptors, making it a high-value target for broad-spectrum autoimmune intervention, particularly in psoriasis, Crohn's disease, and ulcerative colitis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Janssen, AbbVie, Eli Lilly | Psoriasis, Crohn's Disease, Ulcerative Colitis | High-affinity binding assays (Need HEK293-expressed glycosylated ECD-Fc to mimic native receptor binding). |
| Bispecific Antibody | Amgen, Boehringer Ingelheim | Inflammatory Bowel Disease (IBD), Psoriatic Arthritis | Heterodimer validation (Requires both IL-12RB1 and IL-23R/IL-12RB2 proteins to verify simultaneous binding). |
| Small Molecule / Oral Peptides | Protagonist Therapeutics, Pfizer | Oral Inflammatory Disease Therapeutics | Cell-based functional assays (Requires Lentivirus for stable cell line construction to run Flow Cytometry and STAT phosphorylation assays). |